Atsena Therapeutics News and Activities

Acquisition, funding and merger involving Atsena Therapeutics.

• Atsena Therapeutics has just announced a $150 Million fundraising (posted on April 4 2025).

View the org chart displaying its 11 main executives

Most searched biographies at Atsena Therapeutics

• Patrick Ritschel, Chief Executive Officer
• Jackie Grant, Director
• Christina Isacson, Director

Popular executive movements at Atsena Therapeutics

• Kenji Fujita who was Chief Medical Officer, becomes Chief Financial Officer  (posted on January 9 2026).

Create your alert
to follow the executive moves at Atsena Therapeutics.

Atsena Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Atsena Therapeutics

• Cams Live: Shows XXX et Chat Porno Live - BongaCams
• News, Annonces et Concours BongaCams
• Atsena Therapeutics – Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
• Atsena Therapeutics – Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
• Atsena Therapeutics – Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
• Atsena Therapeutics – Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
• Atsena Therapeutics – Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
• Atsena Therapeutics – Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
• Atsena Therapeutics – Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
• Atsena Therapeutics – Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer
• View more press releases Close

Social media about Atsena Therapeutics

• Atsena Therapeutics on Wikipedia, Google News & Yahoo Finance
• Atsena Therapeutics on LinkedIn, X (Twitter) & YouTube